AlphaCentric Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

AlphaCentric Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,500	Closed	-$249K	–	247
2021 Q1	$249K	Buy	+2,500	New	+$292K	0.08%	83
2020 Q4	–	Sell	-225	Closed	-$22K	–	238
2020 Q3	$22K	Buy	+225	New	+$28.1K	0.01%	141

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

AlphaCentric Advisors's RETA Position: Q2 2021 in Review

AlphaCentric Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2021, closing a stake of 2,500 shares — an estimated $249K sold.

AlphaCentric Advisors first reported a position in RETA in Q3 2020 and held it in 2 quarters. The position peaked at $249K in Q1 2021. 194 funds tracked by Wall St. Rank hold RETA as of Q2 2021.

AlphaCentric Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2021 after selling out during the quarter.
AlphaCentric Advisors sold 2,500 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2021, an estimated $249K.
AlphaCentric Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020 and held it in 2 quarters.
AlphaCentric Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $249K in Q1 2021.
194 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2021.

Based on AlphaCentric Advisors's 13F filing for Q2 2021, filed 9 Mar 2022.